All In Biotech

Drug Trial Radar · NCT07220252

Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis

Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Jul 1, 2026

Primary completion

Jan 1, 2030

Study completion Jun 30, 2033

Sponsor

Lead sponsor
TG Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of ublituximab in participants ages 10 to less than (\<)18 years and body weight greater than or equal to (≥)25 kilograms (kg) to less than or equal to (≤)40 kg with RMS (Part A) and to evaluate the non-inferiority of ublituximab compared with fingolimod in pediatric RMS participants with body weight ≥ 25 kg (Part B). The study will further evaluate long-term safety and efficacy of ublituximab in RMS in pediatric participants during its extension period (Part C).

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • UblituximabDrug

    Administered as an intravenous (IV) infusion.

  • PlaceboDrug

    Oral capsule.

  • PlaceboDrug

    IV infusion.

  • FingolimodDrug

    Oral capsule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Area Under the Curve From Week 0 to 24 (AUC0-W24) of UblituximabTime frame: Predose and multiple timepoints up to Week 24
  2. Part A: Maximum Observed Concentration (Cmax) of UblituximabTime frame: Day 1 and Day 15
  3. Part A: Participant B Cell CountsTime frame: Up to Week 24
  4. Part B: Annualized Relapse Rate (ARR)Time frame: Up to 96 weeks
  5. Part C: Annualized Relapse Rate (ARR)Time frame: Up to 168 weeks

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • TG Therapeutics Investigational Trial Site

    Salt Lake City, Utah · Recruiting

  • TG Therapeutics Investigational Trial Site

    Gdansk, Poland · Recruiting

  • TG Therapeutics Investigational Trial Site

    Poznan, Poland · Not yet recruiting

  • TG Therapeutics Investigational Trial Site

    Rzeszów, Poland · Recruiting

  • TG Therapeutics Investigational Trial Site

    Warsaw, Poland · Recruiting

  • TG Therapeutics Investigational Trial Site

    Bratislava, Slovakia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.